keyword
MENU ▼
Read by QxMD icon Read
search

leiomyosarcoma therapy

keyword
https://www.readbyqxmd.com/read/29237802/phase-1-dose-escalation-study-of-anti-ctla-4-antibody-ipilimumab-and-lenalidomide-in-patients-with-advanced-cancers
#1
Divya Sakamuri, Isabella C Glitza, Sonia L Betancourt Cuellar, Vivek Subbiah, Siqing Fu, Apostolia M Tsimberidou, Jennifer J Wheler, David S Hong, Aung Naing, Gerald S Falchook, Michelle A Fanale, Maria E Cabanillas, Filip Janku
Preclinical data suggest that combining a check point inhibition with immunomodulatory derivative can increase anticancer response. We designed a dose escalation study using a 3+3 design to determine the safety, maximum tolerated dose (MTD) or recommended phase 2 dose (R2PD) and dose limiting toxicities (DLT) of the anti-CTLA-4 antibody ipilimumab (1.5-3mg/kg intravenously every 28 days x 4) and lenalidomide (10-25mg orally daily for 21 of 28 days until disease progression or unacceptable toxicity) in advanced cancers...
December 13, 2017: Molecular Cancer Therapeutics
https://www.readbyqxmd.com/read/29216884/intensity-modulated-radiation-therapy-and-surgery-for-management-of-retroperitoneal-sarcomas-a-single-institution-experience
#2
Pippa F Cosper, Jeffrey Olsen, Todd DeWees, Brian A Van Tine, William Hawkins, Jeff Michalski, Imran Zoberi
BACKGROUND: Peri-operative radiation of retroperitoneal sarcomas (RPS) is an important component of multidisciplinary treatment. All retrospective series thus far included patients treated with older radiation therapy (RT) techniques including 2D and 3DRT. Intensity modulated radiation therapy (IMRT) allows for selective dose escalation while sparing adjacent organs. We therefore report the first series of patients with RPS treated solely with IMRT, surgery and chemotherapy. We hypothesized that IMRT would permit safe dose escalation and superior rates of local control (LC) in this high-risk patient population...
December 8, 2017: Radiation Oncology
https://www.readbyqxmd.com/read/29194633/systemic-therapy-in-retroperitoneal-sarcoma-management
#3
REVIEW
Anastasia Constantinidou, Robin L Jones
There is paucity of randomized controlled data on the role of systemic therapy in retroperitoneal sarcomas. The type of systemic therapy used is guided by the histological subtype. The majority of retroperitoneal sarcomas comprising liposarcomas and leiomyosarcomas are by and large chemotherapy insensitive. There is an urgent need for more efficacious systemic therapies in the management of early and advanced stage retroperitoneal sarcomas.
November 30, 2017: Journal of Surgical Oncology
https://www.readbyqxmd.com/read/29193249/turbocharged-bilateral-pedicled-diep-flap-for-reconstruction-of-thigh-defect-without-recipient-vessels-a-case-report
#4
Manuel Fernández Garrido, Nicolás Pereira, Susana López Fernández, Carmen Vega, Jaume Masià
Reconstruction of thigh defects is usually straightforward, but in cases of poor soft tissue quality, free flap reconstruction is not possible due to the absence of recipient vessels. The turbocharge technique may increase the viable, vascularized area of a flap. In this report we present a case of the use of a turbocharged bilateral pedicled DIEP flap for reconstruction of thigh defect without recipient vessels. A 29-year-old woman who underwent neoadjuvant chemotherapy plus radiation therapy for a leiomyosarcoma on the left thigh...
November 29, 2017: Microsurgery
https://www.readbyqxmd.com/read/29185261/pazopanib-monotherapy-in-the-treatment-of-pretreated-metastatic-uterine-sarcoma-a-single-center-retrospective-study
#5
Hyun Jun Kim, Youjin Kim, Su Jin Lee, Jeeyun Lee, Se Hoon Park
OBJECTIVE: In the treatment of metastatic soft tissue sarcoma (STS), pazopanib is considered a standard treatment after failure of chemotherapy. We retrospectively investigated outcomes of pazopanib in patients with metastatic uterine STS. METHODS: A retrospective study was performed on 35 consecutive patients with uterine STS treated with oral pazopanib 800 mg daily as salvage therapy for metastatic disease between September 2013 and December 2015. Endpoints included response rate, survival, and safety...
January 2018: Journal of Gynecologic Oncology
https://www.readbyqxmd.com/read/29176397/a-case-of-heavily-pretreated-metastatic-cardiac-angiosarcoma-treated-successfully-using-eribulin
#6
Chiaki Inagaki, Tatsunori Shimoi, Hitomi Okuma, Akiko Kitano, Akihiko Shimomura, Emi Noguchi, Makoto Kodaira, Mayu Yunokawa, Kan Yonemori, Chikako Shimizu, Akihiko Yoshida, Yasuhiro Fujiwara, Kenji Tamura
Eribulin mesylate (eribulin) is a nontaxane microtubule inhibitor approved in Japan for treating soft tissue sarcoma irrespective of histological subtypes. Thus, our department routinely uses eribulin to treat any histological subtype of sarcoma for patients who have experienced disease progression during standard therapy. However, evidence on the efficacy of eribulin in treating sarcomas that are neither liposarcoma nor leiomyosarcoma is limited. Recently, we encountered a case of a heavily pretreated cardiac angiosarcoma that responded well to eribulin treatment...
November 23, 2017: Anti-cancer Drugs
https://www.readbyqxmd.com/read/29137065/primary-leiomyosarcoma-of-the-bone-a-case-report-and-a-review-of-the-literature
#7
Federica Recine, Alberto Bongiovanni, Roberto Casadei, Federica Pieri, Nada Riva, Alessandro De Vita, Laura Mercatali, Chiara Liverani, Chiara Spadazzi, Giacomo Miserocchi, Valentina Fausti, Dino Amadori, Toni Ibrahim
RATIONALE: Leiomyosarcoma (LMS) is a malignant sarcoma that can occur in different anatomic sites, including the bone, showing similar histological characteristics but heterogeneous clinical behavior and prognosis. Primary bone LMS was first described in 1965. It is a very rare sarcoma, accounting for <0.7% of all primary malignant bone tumors. PATIENT CONCERNS: We report the case of a 52-year-old male with primary bone LMS who presented with a solitary osteolytic lesion with focal cortical destruction in the left clavicle, seen on an x-ray and subsequent computed tomography (CT) scan...
November 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29100621/clinical-and-histopathologic-findings-of-cutaneous-leiomyosarcoma-correlation-with-prognosis-in-12-patients
#8
E Rodríguez-Lomba, I Molina-López, V Parra-Blanco, R Suárez-Fernández, A Pulido-Pérez
INTRODUCTION: Cutaneous leiomyosarcoma is a malignant neoplasm derived from smooth muscle cells. Its low incidence hampers the development of specific protocols for diagnosis and treatment. OBJECTIVES: To describe the clinical and histopathologic characteristics of a series of primary and secondary cutaneous leiomyosarcomas and to determine how these characteristics correlate with prognosis. MATERIAL AND METHODS: We performed an observational, descriptive, retrospective study based on 17 cutaneous leiomyosarcomas in 12 patients diagnosed between January 1, 2000 and December 31, 2015...
October 31, 2017: Actas Dermo-sifiliográficas
https://www.readbyqxmd.com/read/29097650/leiomyosarcoma-of-the-inferior-vena-cava-in-an-hiv-positive-adult-patient-a-case-report-and-review-of-the-literature
#9
Jing Xu, Arash Velayati, Barbara J Berger, Ming Liu, Naga K Sucharita Cheedella, Vladimir Gotlieb
BACKGROUND Leiomyosarcoma is the most common primary malignancy of the inferior vena cava (IVC), and represents approximately 10% of primary retroperitoneal sarcomas. Leiomyosarcoma presents with non-specific symptoms, including abdominal pain or back pain. There is an increased incidence in immunosuppressed individuals. CASE REPORT An unusual presentation of IVC leiomyosarcoma is reported in a 46-year-old female patient infected with human immunodeficiency virus (HIV) who was on highly active antiretroviral therapy (HAART) and who had a normal CD4 count of 934, who presented with back pain...
November 3, 2017: American Journal of Case Reports
https://www.readbyqxmd.com/read/29069276/the-genomic-grade-index-predicts-post-operative-clinical-outcome-in-patients-with-soft-tissue-sarcoma
#10
F Bertucci, A De Nonneville, P Finetti, D Perrot, M Nilbert, A Italiano, A Le Cesne, K M Skubitz, J Y Blay, D Birnbaum
Background: Soft-tissue sarcomas (STS) are a group of rare, heterogeneous and aggressive tumors, with high metastatic risk and relatively few efficient systemic therapies. We hypothesized that the Genomic Grade Index (GGI), a 108-gene signature previously developed in early-stage breast cancer, might improve the prognostic assessment of patients with early-stage STS. Patients and methods: We collected gene expression and clinicopathological data of 678 operated STS, and searched for correlations between the GGI-based classification and clinicopathological variables, including the metastasis-free survival (MFS)...
October 24, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28988646/pembrolizumab-in-advanced-soft-tissue-sarcoma-and-bone-sarcoma-sarc028-a-multicentre-two-cohort-single-arm-open-label-phase-2-trial
#11
Hussein A Tawbi, Melissa Burgess, Vanessa Bolejack, Brian A Van Tine, Scott M Schuetze, James Hu, Sandra D'Angelo, Steven Attia, Richard F Riedel, Dennis A Priebat, Sujana Movva, Lara E Davis, Scott H Okuno, Damon R Reed, John Crowley, Lisa H Butterfield, Ruth Salazar, Jaime Rodriguez-Canales, Alexander J Lazar, Ignacio I Wistuba, Laurence H Baker, Robert G Maki, Denise Reinke, Shreyaskumar Patel
BACKGROUND: Patients with advanced sarcomas have a poor prognosis and few treatment options that improve overall survival. Chemotherapy and targeted therapies offer short-lived disease control. We assessed pembrolizumab, an anti-PD-1 antibody, for safety and activity in patients with advanced soft-tissue sarcoma or bone sarcoma. METHODS: In this two-cohort, single-arm, open-label, phase 2 study, we enrolled patients with soft-tissue sarcoma or bone sarcoma from 12 academic centres in the USA that were members of the Sarcoma Alliance for Research through Collaboration (SARC)...
October 4, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28975823/serotonin-syndrome-complicating-treatment-of-ifosfamide-neurotoxicity-with-methylene-blue
#12
Matthew Snyder, Suhas Gangadhara, Andrew S Brohl, Steven Ludlow, Sowmya Nanjappa
Methylene blue is a widely used treatment for ifosfamide neurotoxicity. We present a case of severe encephalopathy complicating ifosfamide-based therapy for recurrent retroperitoneal leiomyosarcoma. After treatment with methylene blue, the patient experienced clinical decompensation and was diagnosed with serotonin syndrome based on a constellation of clinical findings. Withdrawal of methylene blue and other serotonergic medications led to clinical stabilization and ultimately neurological recovery. Our case highlights the challenge of diagnosing serotonin syndrome in the face of preexisting ifosfamide neurotoxicity, as there is significant clinical overlap between these 2 syndromes...
October 2017: Cancer Control: Journal of the Moffitt Cancer Center
https://www.readbyqxmd.com/read/28930806/management-of-leimyosarcoma-a-survey-among-members-of-the-korean-gynecologic-oncology-group
#13
Mi Kyoung Kim, Taek Sang Lee, Jae-Weon Kim, Jong-Min Lee, Beob Jong Kim, Seok Ju Seong
OBJECTIVE: This study aimed to investigate current clinical management of leiomyosarcoma (LMS) in Korea. MATERIALS AND METHODS: We conducted a Web-based survey among members of the Korean Gynecologic Oncology Group regarding their treatment of LMS. RESULTS: In total, 77 (27.8%) of 277 members responded to the survey. For surgical treatment of stage I LMS, 26.8% indicated total hysterectomy only and 16.9% indicated total hysterectomy with bilateral salpingo-oophorectomy...
November 2017: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/28898798/free-disease-long-term-survival-in-primary-thoracic-spine-leiomyosarcoma-after-total-en-bloc-spondylectomy-a-case-report
#14
José Ramirez-Villaescusa, Adriana Canosa-Fernández, Antonio Martin-Benlloch, David Ruiz-Picazo, Jesús López-Torres Hidalgo
INTRODUCTION: To describe an unusual primary vertebral leiomyosarcoma in thoracic spine. PRESENTATION OF CASE: An isolated lesion of the T11 vertebra in a 62-year-old woman with no neurologic deficit is reported. Imaging findings indicated a nonspecific high-grade malignant lesion. TC-guided biopsy failed thus open incisional biopsy was needed. A diagnosis of low-intermediate mesenchymal sarcoma was made. A total en bloc spondylectomy of T11 was performed with three-column reconstruction...
2017: International Journal of Surgery Case Reports
https://www.readbyqxmd.com/read/28893210/distinct-molecular-subtypes-of-uterine-leiomyosarcoma-respond-differently-to-chemotherapy-treatment
#15
Yang An, Shuzhen Wang, Songlin Li, Lulu Zhang, Dayong Wang, Haojie Wang, Shibai Zhu, Wan Zhu, Yongqiang Li, Wenwu Chen, Shaoping Ji, Xiangqian Guo
BACKGROUND: Uterine leiomyosarcoma (ULMS) is an aggressive form of soft tissue tumors. The molecular heterogeneity and pathogenesis of ULMS are not well understood. METHODS: Expression profiling data were used to determine the possibility and optimal number of ULMS molecular subtypes. Next, clinicopathological characters and molecular pathways were analyzed in each subtype to prospect the clinical applications and progression mechanisms of ULMS. RESULTS: Two distinct molecular subtypes of ULMS were defined based on different gene expression signatures...
September 11, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28868013/efficacy-of-paclitaxel-in-a-patient-with-inoperable-pulmonary-vein-leiomyosarcoma
#16
Shinji Kounami, Hiroshi Tsujimoto, Takayuki Ichikawa, Megumi Yoshiyama, Mitsuru Yuzaki, Yoshiharu Nishimura, Hiroyuki Suzuki
Pulmonary vein leiomyosarcoma is extremely rare and has a poor prognosis. Surgical resection with a wide margin seems to offer the only chance of cure. The role of adjuvant therapy is controversial, and the exact efficacy of chemotherapy has not been observed. In this report, we present an 18-year-old male patient with pulmonary vein leiomyosarcoma in whom the use of paclitaxel (PAX) proved to be effective. Because the tumor originated from the left superior pulmonary vein and diffused into the left atrial wall and the junction of the right superior pulmonary vein and left atrium, the en bloc excision of the tumor was impossible...
May 2017: Case Reports in Oncology
https://www.readbyqxmd.com/read/28865875/photochemical-internalization-pci-of-bleomycin-is-equally-effective-in-two-dissimilar-leiomyosarcoma-xenografts-in-athymic-mice
#17
Simen Sellevold, Qian Peng, Ane Sofie Viset Fremstedal, Kristian Berg
BACKGROUND: Photochemical internalization (PCI) is a novel technique for delivery of active macromolecules into cancerous cells, via light activation of a specific photosensitizer and a low dose systemic drug. Numerous pre-clinical studies and one clinical trial have confirmed the treatment potential in carcinomas. Soft tissue sarcomas are rare and generally resistant to radio- and chemotherapy. Due to treatment resistance and surgical morbidity in sarcoma care, we seek to increase knowledge on PCI effects in sarcomas by studying two different, but closely related leiomyosarcomas...
August 30, 2017: Photodiagnosis and Photodynamic Therapy
https://www.readbyqxmd.com/read/28854066/activity-of-eribulin-in-patients-with-advanced-liposarcoma-demonstrated-in-a-subgroup-analysis-from-a-randomized-phase-iii-study-of-eribulin-versus-dacarbazine
#18
RANDOMIZED CONTROLLED TRIAL
George D Demetri, Patrick Schöffski, Giovanni Grignani, Jean-Yves Blay, Robert G Maki, Brian A Van Tine, Thierry Alcindor, Robin L Jones, David R D'Adamo, Matthew Guo, Sant Chawla
Purpose A phase III study comparing eribulin with dacarbazine in patients with advanced liposarcoma (LPS) or leiomyosarcoma showed a significant improvement in overall survival (OS) for the eribulin arm, with a manageable toxicity profile. We now report the histology-specific subgroup analysis of the efficacy and safety of eribulin compared with dacarbazine in patients with LPS, an independently randomized stratified subgroup of this phase III trial. Methods Patients ≥ 18 years with advanced or metastatic dedifferentiated, myxoid/round cell, or pleomorphic LPS incurable by surgery or radiotherapy were included...
October 20, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28781298/primary-cardiac-leiomyosarcoma-a-27-month-survival-with-surgery-and-chemotherapy
#19
Koji Nakashima, Haruhiko Inatsu, Kazuo Kitamura
The patient was a 39-year-old man hospitalized due to the presence of a cardiac mass and heart failure. Emergency tumor resection and mitral valve replacement were performed. The pathological findings of the tumor led to a diagnosis of cardiac leiomyosarcoma. After the operation, multiple metastases were found. The patient underwent three courses of chemotherapies: adriamycin, ifosfamide, dacarbazine, and mesna (MAID therapy), gemcitabine plus docetaxel, and sunitinib. During MAID therapy, the patient underwent resection of gastrointestinal metastases twice due to gastrointestinal hemorrhaging...
August 15, 2017: Internal Medicine
https://www.readbyqxmd.com/read/28740403/primary-lung-sarcoma-treated-with-stereotactic-ablative-radiotherapy-a-case-report
#20
Seung-Gu Yeo
Primary lung sarcoma (PLS) is an extremely rare, very aggressive malignancy. Surgical removal is considered the treatment of choice, and patients who have been given conventional radiotherapy have had inferior outcomes. This study is the first describing a case of PLS treated with stereotactic ablative radiotherapy (SABR), which precisely targets a small tumor with a markedly higher biologically effective dose than conventional radiotherapy. The patient was an 82-year-old man who was diagnosed with primary lung leiomyosarcoma based on radiology, pathology, and immunohistochemical examinations...
2017: OncoTargets and Therapy
keyword
keyword
115503
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"